Shots:

• The CHMP has adopted a positive opinion recommending the marketing authorization of Abevmy (inj. bevacizumab 100 & 400mg)- which is co-developed by Biocon and Viatris
• The companies expect the EC’s decision in May’2021- which will grant the approval in 27 EU member countries and EEA member states of Norway- Iceland and Liechtenstein. For the UK- MHRA’s reliance procedure” will be followed- and the UK marketing authorization can be expected shortly after the EC decision
• Abevmy is a biosimilar referencing Roche’s Avastin and is a humanized mAb that selectively binds to human VEGF and neutralizes its biological activity. Abevmy is available for all indications of its reference products

 ­ Ref: Biocon Biologics  | Image: PRNewswire